Septerna Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.18next fiscal year
Monitoring Framework
Key Performance Indicators
Collaboration Revenue from Novo Nordisk Partnership Quarterly26.5MTarget: Continued milestone recognition under the $2.2 billion total deal value
Cash and Cash Equivalents Runway Quarterly522.1MTarget: Sufficient to fund operations into 2029
Watch Items
- SEP-479 Phase 1 Clinical Trial ProgressTrigger: Topline safety, PK, and pharmacodynamic data releaseAction: Evaluate transition to Phase 2 clinical development for hypoparathyroidism
- SEP-631 Phase 2b InitiationTrigger: First patient dosed in Chronic Spontaneous Urticaria (CSU) trialAction: Monitor patient recruitment rates and initial safety profiles in the second half of 2026
Research as of 19 Jun 2026